Renal cell carcinoma deep sequencing: Recent developments

Current Oncology Reports

Volumn 14, Issue 3, 2012, Pages 240-248

  Farber, Leslie J ^a,b   Furge, Kyle ^c   Teh, Bin Tean ^b  

^a Duke NUS Graduate Medical School ^*  (United States)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Amplification; Chromophobe RCC; Chromosome; Clear cell RCC (ccRCC); Cytogenetic; Deletion; Exome; Gene; Gene expression; Genitourinary cancers; Hypoxiainducible factor (HIF); Mutation; Oncocytoma; Papillary RCC; Renal; Renal cell carcinoma (RCC); Sequence; Sporadic; Subtypes; Tumor; Von Hippel Lindau (VHL)

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; MITOCHONDRIAL DNA; TRANSCRIPTOME; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CANCER CLASSIFICATION; CANCER GENETICS; CANCER LOCALIZATION; CANCER RESISTANCE; CANCER RISK; CARCINOGENESIS; CHROMOSOME ABERRATION; CHROMOSOME LOSS; CLEAR CELL CARCINOMA; CYTOGENETICS; DISEASE SEVERITY; GENE; GENE EXPRESSION PROFILING; GENE INACTIVATION; GENE SEQUENCE; GENETIC DISORDER; GENETIC HETEROGENEITY; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; KIDNEY DISTAL TUBULE; MISSENSE MUTATION; MOLECULAR GENETICS; NONHUMAN; ONCOCYTOMA; ONCOGENE MYC; PAPILLARY CARCINOMA; PHENOTYPE; SETD2 GENE; SOMATIC MUTATION; TRANSCRIPTION REGULATION; VCAN GENE; VHL GENE; CHROMOSOME ANALYSIS; GENETICS; KIDNEY TUMOR; MUTATION; PATHOLOGY; REVIEW;

CARCINOMA, RENAL CELL; CYTOGENETIC ANALYSIS; GENE EXPRESSION PROFILING; HUMANS; KIDNEY NEOPLASMS; MUTATION; TRANSCRIPTOME;

EID: 84864014029     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-012-0230-3     Document Type: Article

References (115)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
2. Maher ER, Kaelin Jr WG. von Hippel-Lindau disease. Med (Baltimore). 1997;76:381-91.
3. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260 (5112):1317-20.
4. Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008;14(15):4726-34.
5. Beroukhim R, Brunet JP, Di Napoli A, et al. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009;69(11):4674-81.
6. Young AP, Schlisio S, Minamishima YA, et al. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol. 2008;10:361-9.
7. Young AP, Kaelin Jr WG. Senescence triggered by the loss of the VHL tumor suppressor. Cell Cycle. 2008;7(12):1709-12.
8. •• Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011;469(7331):539-42. This study identified the most promising cancer gene associated with ccRCC since VHL as a prognostic and predictive marker.
9. van Haaften G, Dalgliesh GL, Davies H, et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet. 2009;41(5):521-3.
10. Dalgliesh GL, Furge K, Greenman C, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 2010;463(7279):360-3.
11. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532-43.
12. Jones S, Wang TL, Shih IeM, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330(6001):228-31.
13. Wang X, Nagl Jr NG, Flowers S, et al. Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors. Int J Cancer. 2004;112(4):636.
14. Orlovsky K, Kalinkovich A, Rozovskaia T, et al. Downregulation of homeobox genes MEIS1 and HOXA in MLL-rearranged acute leukemia impairs engraftment and reduces proliferation. Proc Natl Acad Sci U S A. 2011;108(19):7956-61.
15. Niu X, Zhang T, Liao L, et al. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C. Oncogene. 2011 Jul 4
16. Abidi FE, Holloway L, Moore CA, et al. Mutations in JARID1C are associated with X-linked mental retardation, short stature and hyperreflexia. J Med Genet. 2008;45(12):787-93.
17. Adegbola A, Gao H, Sommer S, Browning M. A novel mutation in JARID1C/SMCX in a patient with autism spectrum disorder (ASD). Am J Med Genet A. 2008;146A(4):505-11.
18. Santos-Rebouças CB, Fintelman-Rodrigues N, Jensen LR, et al. A novel nonsense mutation in KDM5C/JARID1C gene causing intellectual disability, short stature and speech delay. Neurosci Lett. 2011;498(1):67-71.
19. Edmunds JW, Mahadevan LC, Clayton AL. Dynamic histone H3 methylation during gene induction: HYPB/Setd2 mediates all H3K36 trimethylation. EMBO J. 2008;27(2):406-20.
20. Duns G, van den Berg E, van Duivenbode I, et al. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma. Cancer Res. 2010;70 (11):4287-91.
21. Guo G, Gui Y, Gao S, Tang A, et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet. 2012;44(1):17-9.
22. Elfving P, Mandahl N, Lundgren R, et al. Prognostic implications of cytogenetic findings in kidney cancer. Br J Urol. 1997;80 (5):698-706.
23. Schullerus D, Herbers J, Chudek J, Kanamaru H, Kovacs G. Loss of heterozygosity at chromosomes 8p, 9p, and 14q is associated with stage and grade of non-papillary renal cell carcinomas. J Pathol. 1997;183(2):151-5.
24. Herbers J, Schullerus D, Müller H, et al. Significance of chromosome arm 14q loss in nonpapillary renal cell carcinomas. Gene Chromosome Canc. 1997;19(1):29-35.
25. Alimov A, Sundelin B, Wang N, Larsson C, Bergerheim U. Loss of 14q31-q32.2 in renal cell carcinoma is associated with high malignancy grade and poor survival. Int J Oncol. 2004;25 (1):179-85.
26. Shen C, Beroukhim R, Schumacher SE, et al. Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. Canc Discov. 2011;1:222-35.
27. • Dondeti VR, Wubbenhorst B, Lal P, et al. Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res. 2012;72(1):112-21. This study advances our understanding ccRCCs by identifying two potential chromosome 5q oncogenes.
28. • Purdue MP, Johansson M, Zelenika D, et al. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet. 2011;43(1):60-5. This study directly implicates mutations in the HIF to RCC tumorigenesis.
29. Han SS, Yeager M, Moore LE, et al. The chromosome 2p21 region harbors a complex genetic architecture for association with risk for renal cell carcinoma. Hum Mol Genet. 2011, Dec 20
30. Duesberg P, Stindl R, Li R, et al. Aneuploidy verses gene mutations as cause of cancer. Curr Sci. 2001;81:490-500.
31. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183 (2):131-3.
32. Klatte T, Pantuck AJ, Said JW, et al. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res. 2009;15(4):1162-9.
33. Toma MI, Grosser M, Herr A, et al. Loss of heterozygosity and copy number abnormality in clear cell renal cell carcinoma discovered by high-density affymetrix 10 K single nucleotide polymorphism mapping array. Neoplasia. 2008;10(7):634-42.
34. Brunelli M, Eccher A, Gobbo S, et al. Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. Mod Pathol. 2008;21(1):1-6.
35. Hagenkord JM, Parwani AV, Lyons-Weiler MA, et al. Virtual karyotyping with SNP microarrays reduces uncertainty in the diagnosis of renal epithelial tumors. Diagn Pathol. 2008;3:44.
36. Cohen AJ, Li FP, Berg S, et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med. 1979;301(11):592-5.
37. Zbar B, Brauch H, Talmadge C, Linehan M. Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature. 1987;327(6124):721-4.
38. Kovacs G, Brusa P. Recurrent genomic rearrangements are not at the fragile sites on chromosomes 3 and 5 in human renal cell carcinomas. Hum Genet. 1988;80:99-101.
39. Glover TW, Coyle-Morris JF, Li FP, et al. Translocation t(3;8) (p14.2;q24.1) in renal cell carcinoma affects expression of the common fragile site at 3p14(FRA3B) in lymphocytes. Canc Genet Cytogenet. 1988;31(1):69-73.
40. Tajara EH, Berger CS, Hecht BK, et al. Loss of common 3p14 fragile site expression in renal cell carcinoma with deletion breakpoint at 3p14. Canc Genet Cytogenet. 1988;31(1):75-82.
41. Shridhar V, Rivard S, Shridhar R, et al. A gene from human chromosomal band 3p21.1 encodes a highly conserved argininerich protein and is mutated in renal cell carcinomas. Oncogene. 1996;12(9):1931-9.
42. Gunawan B, Huber W, Holtrup M, et al. Prognostic impacts of cytogenetic findings in clear cell renal cell carcinoma: Gain of 5q31-qter predicts a distinct clinical phenotype with favorable prognosis. Cancer Res. 2001;61:7731-8.
43. Monzon FA, Alvarez K, Peterson L, et al. Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Mod Pathol. 2011;24:1470-9.
44. Moch H, Presti Jr JC, Sauter G, et al. Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma. Cancer Res. 1996;56(1):27-30.
45. Nagao K, Yamaguchi S, Matsuyama H, et al. Allelic loss of 3p25 associated with alterations of 5q22.3 approximately q23.2 may affect the prognosis of conventional renal cell carcinoma. Canc Genet Cytogenet. 2005;160(1):43-8.
46. Junker K, Moravek P, Podhola M, et al. Genetic alterations in metastatic renal cell carcinoma detected by comparative genomic hybridization: Correlation with clinical and histological data. Int J Oncol. 2000;17(5):903-8.
47. Amin MB, Corless CL, Renshaw AA, Tickoo SK, Kubus J, Schultz DS. Papillary (chromophil) renal cell carcinoma: Histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases. Am J Surg Pathol. 1997;21(6):621-35.
48. Jiang F, Richter J, Schraml P, et al. Chromosomal imbalances in papillary renal cell carcinoma: Genetic differences between histological subtypes. Am J Pathol. 1998;153(5):1467-73.
49. Delahunt B, Furge K, Greenman C, et al. Morphologic typing of papillary renal cell carcinoma: Comparison of growth kinetics and patient survival in 66 cases. Hum Pathol. 2001;32(6):590-5.
50. Pignot G, Elie C, Conquy S, et al. Survival analysis of 130 patients with papillary renal cell carcinoma: Prognostic utility of type 1 and type 2 subclassification. Urology. 2007;69(2):230-5.
51. Gunawan B, von Heydebreck A, Fritsch T, et al. Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: Evidence for a cytogenetic evolution of type 2 from type 1 tumors. Cancer Res. 2003;63(19):6200-5.
52. Waldert M, Haitel A, Marberger M, et al. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC. BJU Int. 2008;102(10):1381-4.
53. Yang XJ, Tan MH, Kim HL, et al. A molecular classification of papillary renal cell carcinoma. Cancer Res. 2005;65(13):5628-37.
54. Furge KA, Tan MH, Dykema K, et al. Identification of deregulated oncogenic pathways in renal cell carcinoma: An integrated oncogenomic approach based on gene expression profiling. Oncogene. 2007;26(9):1346-50.
55. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet. 1997;16(1):68-73.
56. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 1999;18(14):2343-50.
57. Lubensky IA, Schmidt L, Zhuang Z, et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol. 1999;155 (2):517-26.
58. Bellon SF, Kaplan-Lefko P, Yang Y, et al. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem. 2008;283(5):2675-83.
59. Koski TA, Lehtonen HJ, Jee KJ, et al. Array comparative genomic hybridization identifies a distinct DNA copy number profile in renal cell cancer associated with hereditary leiomyomatosis and renal cell cancer. Gene Chromosome Canc. 2009;48(7):544-51.
60. Looyenga BD, Furge KA, Dykema KJ, et al. Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proc Natl Acad Sci U S A. 2011;108(4):1439-44.
61. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30(4):406-10.
62. Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet. 2003;73(1):95-106.
63. Lehtonen HJ, Kiuru M, Ylisaukko-Oja SK, et al. Increased risk of cancer in patients with fumarate hydratase germline mutation. J Med Genet. 2006;43(6):523-6.
64. Refae MA, Wong N, Patenaude F, et al. Hereditary leiomyomatosis and renal cell cancer: An unusual and aggressive form of hereditary renal carcinoma. Nat Clin Pract Oncol. 2007;4(4):256-61.
65. Toro JR, Wei MH, Glenn GM, et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: A new series of 50 families and a review of published reports. J Med Genet. 2008;45(6):321-31.
66. Wei MH, Toure O, Glenn GM, et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet. 2006;43(1):18-27.
67. Lehtonen HJ, Blanco I, Piulats JM, et al. Conventional renal cancer in a patient with fumarate hydratase mutation. Hum Pathol. 2007;38(5):793-6.
68. Adam J, Hatipoglu E, O'Flaherty L, et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathways: Roles for fumarate in KEAP1 succination and Nrf2 signaling. Canc Cell. 2011;20:524-37.
69. Ooi A, Wong JC, Petillo D, et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Canc Cell. 2011;20:511-23.
70. Delahunt B, Eble JN. Papillary renal cell carcinoma: A clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol. 1997;10(6):537-44.
71. Schuetz AN, Yin-Goen Q, Amin MB, et al. Molecular classification of renal tumors by gene expression profiling. J Mol Diagn. 2005;7(2):206-18.
72. Mayr JA, Meierhofer D, Zimmermann F, et al. Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma. Clin Cancer Res. 2008;14(8):2270-5.
73. Gasparre G, Hervouet E, de Laplanche E, et al. Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma. Hum Mol Genet. 2008;17(7):986-95.
74. Kovacs A, Storkel S, Thoenes W, Kovacs G. Mitochondrial and chromosomal DNA alterations in human chromophobe renal cell carcinomas. J Pathol. 1992;167(3):273-7.
75. Welter C, Kovacs G, Seitz G, Blin N. Alteration of mitochondrial DNA in human oncocytomas. Gene Chromosome Canc. 1989;1 (1):79-82.
76. Brunelli M, Eble JN, Zhang S, et al. Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. Mod Pathol. 2005;18(2):161-9.
77. Takahashi M, Yang XJ, Sugimura J, et al. Molecular subclassification of kidney cancer and the discovery of new diagnostic markers. Oncogene. 2003;22:6810-8.
78. Higgins JP, Shinghal R, Gill H, et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol. 2003;162(3):925-32.
79. Brown JA, Takahashi S, Alcaraz A, et al. Fluorescence in situ hybriziation analysis of renal oncocytoma reveals frequent loss of chromosomes Y and 1. J Urol. 1996;156:31-5.
80. Paner GP, Lindgren V, Jacobson K, et al. High incidence of chromosome 1 abnormalities in a series of 27 renal oncocytomas: Cytogenetic and fluorescence in situ hybridzation studies. Arch Pathol Lab Med. 2006;131:81-5.
81. Fuzesi L, Gunawan B, Braun S, et al. Cytogenetic analysis of 11 renal oncocytomas: Further evidence of structural rearrangments of 11q13 as a characteristics of chromosomal anomaly. Canc Genet Cytogenet. 1999;107:1-6.
82. Takahashi M, Rhodes DR, Furge KA, et al. Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification. Proc Natl Acad Sci U S A. 2001;98 (17):9754-9.
83. Gieseg MA, Cody T, Man MZ, et al. Expression profiling of human renal carcinomas with functional taxonomic analysis. BMC Bioinforma. 2002;3:26.
84. Boer JM, Huber WK, Sültmann H, et al. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res. 2001;11(11):1861-70.
85. Jones J, Otu H, Spentzos D, et al. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res. 2005;11 (16):5730-9.
86. Liou LS, Shi T, Duan ZH, et al. Microarray gene expression profiling and analysis in renal cell carcinoma. BMC Urol. 2004;4:9.
87. Yamazaki K, Sakamoto M, Ohta T, et al. Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene. 2003;22 (6):847-52.
88. Skubitz KM, Skubitz AP. Differential gene expression in renalcell cancer. J Lab Clin Med. 2002;140(1):52-64.
89. Skubitz KM, Zimmermann W, Kammerer R, et al. Differential gene expression identifies subgroups of renal cell carcinoma. J Lab Clin Med. 2006;147(5):250-67.
90. Furge KA, Dykema K, Petillo D, et al. Combining differential expression, chromosomal and pathway analyses for the molecular characterization of renal cell carcinoma. Can Urol Assoc J. 2007;1(2 Suppl):S21-7.
91. Zhou M, Kort E, Hoekstra P, et al. Adult cystic nephroma and mixed epithelial and stromal tumor of the kidney are the same disease entity: Molecular and histologic evidence. Am J Surg Pathol. 2009;33(1):72-80.
92. Moch H, Schraml P, Bubendorf L, et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol. 1999;154 (4):981-6.
93. Li G, Barthelemy A, Feng G, et al. S100A1: A powerful marker to differentiate chromophobe renal cell carcinoma from renal oncocytoma. Histopathology. 2007;50(5):642-7.
94. Lin F, Yang W, Betten M, et al. Expression of S-100 protein in renal cell neoplasms. Hum Pathol. 2006;37(4):462-70.
95. Rocca PC, Brunelli M, Gobbo S, et al. Diagnostic utility of S100A1 expression in renal cell neoplasms: An immunohistochemical and quantitative RT-PCR study. Mod Pathol. 2007;20 (7):722-8.
96. Yao M, Huang Y, Shioi K, et al. Expression of adipose differentiation-related protein: A predictor of cancer-specific survival in clear cell renal carcinoma. Clin Cancer Res. 2007;13 (1):152-60.
97. Kosari F, Parker AS, Kube DM, et al. Clear cell renal cell carcinoma: Gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res. 2005;11(14):5128-39.
98. Zhao H, Ljungberg B, Grankvist K, et al. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med. 2006;3(1):e13.
99. Tsui KH, Shvarts O, Smith RB, et al. Prognostic indicators for renal cell carcinoma: A multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol. 2000;163 (4):1090-5. quiz 1295.
100. Gettman MT, Blute ML, Spotts B, et al. Pathologic staging of renal cell carcinoma: Significance of tumor classification with the 1997 TNM staging system. Cancer. 2001;91(2):354-61.
101. Han KR, Bleumer I, Pantuck AJ, et al. Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. J Urol. 2003;170(6 Pt 1):2221-4.
102. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19(6):1649-57.
103. Staller P, Sulitkova J, Lisztwan J, et al. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature. 2003;425(6955):307-11.
104. Yao M, Tabuchi H, Nagashima Y, et al. Gene expression analysis of renal carcinoma: Adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J Pathol. 2005;205(3):377-87.
105. Desai KV, Xiao N, Wang W, et al. Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci U S A. 2002;99(10):6967-72.
106. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Canc Cell. 2002;1(1):75-87.
107. Huang E, Ishida S, Pittman J, et al. Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet. 2003;34:226-30.
108. Sweet-Cordero A, Mukherjee S, Subramanian A, et al. An oncogenic KRAS2 expression signature identified by crossspecies gene-expression analysis. Nat Genet. 2005;37(1):48-55.
109. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006;439:353-7.
110. Chi JT, Wang Z, Nuyten DS, et al. Gene expression programs in response to hypoxia: Cell type specificity and prognostic significance in human cancers. PLoS Med. 2006;3(3):e47.
111. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-50.
112. Kim S, Volsky DJ. PAGE: Parametric analysis of gene set enrichment. BMC Bioinforma. 2005;6:144.
113. Riss J, Khanna C, Koo S, et al. Cancers as wounds that do not heal: Differences and similarities between renal regeneration/ repair and renal cell carcinoma. Cancer Res. 2006;66 (14):7216-24.
114. Copland JA, Luxon BA, Ajani L, et al. Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression. Oncogene. 2003;22(39):8053-62.
115. Furge KA, Chen J, Koeman J, et al. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res. 2007;67(7):3171-6.